Verici Receives Medicare Coverage for Tutivia Diagnostic Test
Why we think this is neutral
This RNS announcement is a general update on Verici Dx receiving Medicare coverage for its Tutivia diagnostic test. While this is positive news for the company, it does not contain any of the mandatory news types that would require a more detailed analysis.
Key Points
- Verici Dx receives Medicare coverage for Tutivia diagnostic test
- Tutivia is a post-kidney transplant blood test that reports the patient's risk of acute rejection
- Medicare coverage will improve patient access to the Tutivia test
Summary
The healthcare company has received Medicare coverage for its Tutivia diagnostic test, which will improve patient access to the product.
Verici Dx plc (AIM: VRCI) has received a positive Technical Assessment by Palmetto GBA, a Medicare Administrative Contractor, allowing for Medicare coverage of its Tutivia™ assay, a diagnostic test for acute rejection in kidney transplant patients. This will support broader access for renal transplant patients to the Tutivia™ test.
GENERAL UPDATE